Last updated: 2026-09-15 20:32:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Alvotech (ALVO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5.03, with a market capitalization of $1.89B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.94 to $9.25. This page covers its latest market performance, valuation, price trends and company information.
$1.89B | |
$5.05 | |
$18.00 | |
$2.94 | |
$5.05 | |
571.74K | |
934.45K | |
-- | |
$9.25 | |
$2.94 | |
-- | |
-- |
Alvotech (ALVO) is trading at $5.03 in after-hours trading as of 2026-09-15 20:16:00, down 0.50% ($0.02) from the regular-session close of $5.05.
After-hours trading shows how investors are pricing ALVO after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Alvotech (ALVO) moved from $5.38 to $5.03, representing a decline of 6.60% ($0.35).
The stock traded between $4.93 and $5.47 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 613.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.0%
ALVO is currently trading at $5.03, placing it 33.0% of the way from its 52-week low of $2.94 to its 52-week high of $9.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
| Employees | 1460 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alvotech (ALVO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.